Acitretin/etretinate embryopathy is a rare condition caused by the use of acitretin or etretinate during pregnancy. These medications are used to treat severe psoriasis and other skin conditions. Exposure to these medications during pregnancy can cause a range of birth defects, including heart defects, facial malformations, and central nervous system abnormalities.

The symptoms of Acitretin/etretinate embryopathy include:

-Craniofacial abnormalities such as cleft lip and/or palate, micrognathia, and low-set ears
-Cardiac defects such as ventricular septal defect, atrial septal defect, and patent ductus arteriosus
-Neurological abnormalities such as hydrocephalus, microcephaly, and mental retardation
-Skeletal abnormalities such as syndactyly, polydactyly, and clubfoot
-Growth retardation
-Hearing loss
-Eye abnormalities such as microphthalmia, strabismus, and cataracts
-Renal abnormalities such as hydronephrosis and renal dysplasia
-Gastrointestinal abnormalities such as esoph

Acitretin/etretinate embryopathy is caused by the use of acitretin or etretinate during pregnancy. These medications are used to treat severe psoriasis, but they can cause birth defects if taken during pregnancy. The risk of birth defects is highest during the first trimester of pregnancy, when the baby’s organs are forming. The risk is also higher if the mother takes a higher dose of the medication.

The treatment for Acitretin/etretinate embryopathy is primarily supportive. This includes monitoring for any potential complications, such as growth and developmental delays, and providing appropriate interventions to address any issues that arise. In some cases, physical therapy, occupational therapy, and speech therapy may be recommended to help with any motor or cognitive delays. Additionally, medications may be prescribed to help manage any associated medical conditions, such as seizures or vision problems.

1. Maternal use of acitretin/etretinate during pregnancy.
2. Maternal use of acitretin/etretinate in the first trimester of pregnancy.
3. Maternal use of acitretin/etretinate at high doses.
4. Maternal use of acitretin/etretinate for a prolonged period of time.
5. Maternal use of acitretin/etretinate in combination with other teratogenic medications.
6. Maternal use of acitretin/etretinate in combination with alcohol or other substances that may increase the risk of teratogenicity.
7. Maternal age over 35 years.
8. Maternal history of diabetes, hypertension, or other chronic medical conditions.
9. Maternal history of drug or

Unfortunately, there is no cure for Acitretin/etretinate embryopathy. However, there are medications that can help manage the symptoms associated with the condition. These medications include anticonvulsants, anti-inflammatory drugs, and corticosteroids. Additionally, physical therapy and occupational therapy can help improve mobility and reduce pain.